Therapeutic Class |
Antiprotozoal |
Indications |
Treatment of parasitic infections, including amebiasis, giardiasis, and Trichomonas vaginalis; treatment of infections due to susceptible strains of anaerobic bacteria. |
Adult Doses |
Oral Intravenous Reconstitution: Dilute to a concentration of ≤5 mg/ml. |
Pediatric Doses |
Oral Reconstitution: Dilute to a concentration of ≤5 mg/ml. |
Doses in Renal impairment |
Haemodialysis patients: Give a supplemental dose (50% of the usual dose) before dialysis. |
Doses in Hepatic impairment |
Severe: Double the interval between doses. |
Contraindications |
Hypersensitivity to ornidazole or to other nitroimidazole derivatives. |
Warnings / Precautions |
Renal and hepatic impairment. CNS diseases e.g. epilepsy or multiple sclerosis. May impair ability to drive or operate machinery. Pregnancy and lactation. |
Adverse Reactions |
Somnolence, headache, nausea, vomiting, dizziness, tremor, rigidity, poor coordination, seizures, tiredness, vertigo, temporary loss of consciousness and signs of sensory or mixed peripheral neuropathy, taste disturbances, abnormal LFTs, skin reactions. |
Drug Interactions |
Potentiates effect of coumarin-type oral anticoagulants. Prolongs the muscle-relaxant effect of vecuronium bromide. |
Mechanism of Actions |
Ornidazole is a 5-nitroimidazole derivative active against protozoa and anaerobic bacteria. It is converted to reduction products that interact with DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. |
Pharmacodynamics |
Absorption: Readily absorbed (oral and intravaginal); peak plasma concentrations after 2 hr (oral), 12 hr (intravaginal). |
ATC Classification |
G01AF06,J01XD03,P01AB03 |
GenericPedia Classification |
|
Available As |
|
Ornidazole
Post Review about Ornidazole Click here to cancel reply.
Ornidazole Containing Brands
Ornidazole is used in following diseases
Drug - Drug Interactions of Ornidazole
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.